Table 1.
Baseline characteristics of 1882 patients with ACS referred for coronary angiography in four Swiss Academic Centers
| Demographics | |
| Age, mean (±SD) | 62.0 (11.8) |
| Male | 1501 (79.8) |
| University education, | 284 (15.5) |
| Married or partnership | 1274 (67.8) |
| No employment or retired | 899 (48.1) |
| Living with someone | 1445 (76.9) |
| CVRF or medical history | |
| BMI (kg/m2) categories, n (%) | |
| <25 kg/m² | 600 (32.3) |
| 25.0–29.9 kg/m² | 865 (78.9) |
| ≥30.0 kg/m² | 392 (21.1) |
| Current smoking | 748 (39.7) |
| Diabetes | 313 (16.6) |
| Hypercholesterolaemia | 1146 (61.0) |
| Hypertension | 1009 (53.6) |
| Previous MI | 269 (14.3) |
| Hospitalisation data | |
| ACS diagnosis | |
| Unstable angina, n (%) | 84 (4.5) |
| NSTEMI, n (%) | 746 (39.6) |
| STEMI, n (%) | 1052 (55.9) |
| Index revascularisation | |
| PCI with stent | 1642 (87.3) |
| PCI with balloon | 100 (5.3) |
| Conservative | 140 (7.4) |
| Killip classification | |
| Killip 1 | 1675 (89.9) |
| Killip 2 | 131 (7.0) |
| Killip 3 | 25 (1.3) |
| Killip 4 | 32 (1.7) |
| Discharge data | |
| Attendance to CR, n (%) | 1308 (70.6) |
| Documentation of aspirin, n (%) | 1881 (100) |
| Documentation of P2Y12 inhibitors if PCI, n (%) | 1684 (99.5) |
| Documentation of statin, n (%) | 1861 (98.9) |
| Documentation of β-blocker, n (%) | 1764 (93.7) |
| Documentation of ACEI/ARB, n (%) | 1875 (99.6) |
ACS, acute coronary syndromes; ACEI, ACE inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CR, cardiac rehabilitation; CVRF, cardiovascular risk factor; EQ-5D, EuroQol five-dimensional questionnaire; Killip, MI, myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina.